Ventyx Biosciences, Inc.
NASDAQ:VTYX
2.15 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 1.076 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.316 | 0.408 | 0.403 | 0.265 | 0.139 | 0.134 | 0.15 | 0.127 | 0.103 | 0.09 | 0.016 | 0.009 | 0.004 | 0.001 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.316 | -0.408 | 0.673 | -0.265 | -0.139 | -0.134 | -0.15 | -0.127 | -0.103 | -0.09 | -0.016 | -0.009 | -0.004 | -0.001 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0.625 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 27.805 | 33.747 | 40.32 | 49.75 | 48.56 | 35.437 | 30.185 | 25.468 | 14.676 | 17.409 | 13.824 | 10.545 | 9.511 | 24.601 | 1.307 | 1.99 | 1.535 | 1.535 |
| General & Administrative Expenses
| 7.907 | 8.021 | 8.326 | 8.201 | 8.585 | 7.115 | 8.386 | 5.952 | 5.722 | 5.338 | 4.002 | 2.242 | 1.675 | 0.747 | 0.133 | 0.245 | 0.153 | 0.153 |
| Selling & Marketing Expenses
| -0.316 | -0.408 | -0.903 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 7.591 | 7.613 | 7.423 | 8.201 | 8.585 | 7.115 | 8.386 | 5.952 | 5.722 | 5.338 | 4.002 | 2.242 | 1.675 | 0.747 | 0.133 | 0.245 | 0.153 | 0.153 |
| Other Expenses
| -0.021 | -0.031 | -0.028 | -0.008 | -0.005 | -0.001 | 0.172 | 0.958 | 0.038 | 0.015 | 0.058 | 0.013 | -4.373 | -1.147 | 0 | -0.001 | 0 | 0 |
| Operating Expenses
| 35.396 | 41.36 | 47.743 | 57.951 | 57.145 | 42.552 | 38.571 | 31.42 | 20.398 | 22.747 | 17.826 | 12.787 | 11.186 | 25.348 | 1.44 | 2.235 | 2.103 | 2.103 |
| Operating Income
| -35.712 | -41.768 | -48.146 | -57.951 | -57.145 | -42.552 | -38.571 | -31.42 | -20.398 | -22.747 | -17.826 | -12.787 | -11.186 | -25.348 | -1.44 | -2.235 | -1.687 | -1.687 |
| Operating Income Ratio
| 0 | 0 | -44.745 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 3.762 | 3.196 | 1.393 | 3.924 | -0.005 | 3.621 | 3.357 | 0.958 | 0.038 | 0.015 | 0.058 | 0.013 | -4.373 | -12.198 | -15.109 | -4.826 | -0.471 | -0.471 |
| Income Before Tax
| -31.95 | -38.572 | -46.753 | -54.027 | -53.251 | -38.931 | -35.214 | -30.462 | -20.018 | -22.732 | -17.768 | -12.774 | -15.559 | -37.645 | -16.702 | -7.155 | -2.158 | -2.158 |
| Income Before Tax Ratio
| 0 | 0 | -43.451 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0.365 | 7.785 | -0.265 | -3.899 | -3.621 | -0.15 | -0.958 | -0.342 | -0.015 | 0.058 | 0.013 | -4.373 | -1.048 | -1.287 | 0.094 | -0.471 | -0.471 |
| Net Income
| -31.95 | -38.572 | -46.753 | -54.027 | -53.251 | -35.31 | -35.064 | -29.504 | -20.018 | -22.717 | -17.768 | -12.774 | -15.559 | -37.645 | -16.702 | -7.155 | -2.158 | -2.158 |
| Net Income Ratio
| 0 | 0 | -43.451 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.45 | -0.62 | -0.79 | -0.92 | -0.91 | -0.61 | -0.62 | -0.57 | -0.39 | -0.45 | -0.38 | -0.27 | -0.74 | -1.78 | -0.79 | -0.34 | -1.1 | -1.1 |
| EPS Diluted
| -0.45 | -0.62 | -0.79 | -0.92 | -0.91 | -0.61 | -0.62 | -0.57 | -0.39 | -0.45 | -0.38 | -0.27 | -0.74 | -1.78 | -0.79 | -0.34 | -1.1 | -1.1 |
| EBITDA
| -35.396 | -41.36 | -47.743 | -57.951 | -57.006 | -42.552 | -35.214 | -30.335 | -20.295 | -22.642 | -17.752 | -12.765 | -15.555 | -26.494 | -1.44 | -2.236 | -0.471 | -0.471 |
| EBITDA Ratio
| 0 | 0 | -44.371 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |